1. Academic Validation
  2. Interleukin-1β triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells

Interleukin-1β triggers matrix metalloprotease-3 expression through p65/RelA activation in melanoma cells

  • PLoS One. 2022 Nov 29;17(11):e0278220. doi: 10.1371/journal.pone.0278220.
Junichi Nunomura 1 Rei Nakano 1 2 3 Atsuto Naruke 1 Yoko Suwabe 1 Masumi Nakano 1 Naoya Yachiku 1 Manami Kuji 1 Mana Sugimura 1 Shinichi Namba 1 Taku Kitanaka 1 Nanako Kitanaka 1 Hiroshi Sugiya 1 3 Tomohiro Nakayama 1
Affiliations

Affiliations

  • 1 Laboratories of Veterinary Radiotherapy, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa, Japan.
  • 2 Laboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan.
  • 3 Japan Animal Specialty Medical Institute, Tsuzuki, Yokohama, Kanagawa, Japan.
Abstract

Melanoma shows highly aggressive behavior (i.e., local invasion and metastasis). Matrix metalloprotease-3 (MMP-3), a zinc-dependent endopeptidase, degrades several extracellular substrates and contributes to local invasion by creating a microenvironment suitable for tumor development. Here, we report that interleukin-1β (IL-1β) triggers the MMP-3 expression in canine melanoma cells. The activity of MMP-3 in the culture supernatant was increased in IL-1β-treated melanoma cells. IL-1β time- and dose-dependently provoked the mRNA expression of MMP-3. IL-1β induced the migration of melanoma cells; however, this migration was attenuated by UK356618, an MMP-3 Inhibitor. When the cells were treated with the nuclear factor-κB (NF-κB) inhibitor TPCA-1, the inhibition of MMP-3 expression was observed. In IL-1β-treated cells, the phosphorylation both of p65/RelA and p105 was detected, indicating NF-κB pathway activation. In p65/RelA-depleted melanoma cells, IL-1β-mediated mRNA expression of MMP-3 was inhibited, whereas this reduction was not observed in p105-depleted cells. These findings suggest that MMP-3 expression in melanoma cells is regulated through IL-1β-mediated p65/RelA activation, which is involved in melanoma cell migration.

Figures
Products